Global data: the market size of psoriasis drugs will increase significantly in the next 10 years

Source: Ding Xiangyuan 2016-04-18 according to global data, a research and consulting company, the market size of psoriasis treatment drugs will increase from $6.6 billion in 2014 to $13.3 billion in 2024, more than doubling This significant increase represents an annual growth rate of 7.3%, which is an encouraging statistic for 2-3% of patients worldwide who are seeking to reduce this chronic hereditary skin disease The psoriasis market is driven by a number of factors The impressive growth was due to the launch of new psoriasis products and the expansion of the market for existing therapeutic drugs, such as dimethyl fumarate from Germany to the United States and major European markets In addition, the growth of the market also benefited from the rapid expansion of the market for bio similar drugs currently on the market The patents of the best-selling brand drugs, such as the TNF inhibitor sumac and enaxi universal infliximab, will expire in the forecast period in the United States, France, Germany, Italy, Spain and the United Kingdom, and the products of different grades will inevitably spread and grow in the next few years "Although the market for psoriasis will be competitive, new products such as Lilly's anti IL-17 drug ixekizumab and Johnson's IL-23 inhibitor guselkumab are expected to achieve more than 10% by the end of the forecast period," explained Dr Sanyal, an analyst in charge of immunology at GlobalData Billion dollars in sales, mainly due to the high clinical efficacy and safety of two drugs "Other R & D line drugs with abnormal efficacy and safety include tildrakizumab of mosadon and brodalumab of AstraZeneca / Valeant For the two drugs, there is still a long way to go to solve the current demand, provide long-term results without side effects or increase the risk of complications "